KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Research & Development (2016 - 2025)

Historic Research & Development for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $509.4 million.

  • Biogen's Research & Development fell 75.98% to $509.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year decrease of 1018.53%. This contributed to the annual value of $1.8 billion for FY2025, which is 1018.53% down from last year.
  • Latest data reveals that Biogen reported Research & Development of $509.4 million as of Q4 2025, which was down 75.98% from $436.1 million recorded in Q3 2025.
  • Over the past 5 years, Biogen's Research & Development peaked at $736.3 million during Q3 2023, and registered a low of $399.0 million during Q2 2025.
  • Over the past 5 years, Biogen's median Research & Development value was $538.9 million (recorded in 2022), while the average stood at $546.8 million.
  • Examining YoY changes over the last 5 years, Biogen's Research & Development showed a top increase of 160072.64% in 2021 and a maximum decrease of 5947.51% in 2021.
  • Over the past 5 years, Biogen's Research & Development (Quarter) stood at $699.5 million in 2021, then fell by 14.0% to $601.6 million in 2022, then fell by 7.86% to $554.3 million in 2023, then fell by 7.4% to $513.3 million in 2024, then dropped by 0.76% to $509.4 million in 2025.
  • Its last three reported values are $509.4 million in Q4 2025, $436.1 million for Q3 2025, and $399.0 million during Q2 2025.